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ÖZET 
Giriş: Primer Sjögren Sendromlu (PSS) hastaların %20’sinde nörolojik tutulum olduğu 
gösterilmiştir. Olguların %57’sinde ise ilk olarak nörolojik belirtiler ortaya çıkmaktadır. 
Nörologların bu belirtileri erkenden tespit etmesi ve PSS tedavisine başlanması ile 
hastaların yaşamı kurtarılabilmekte ve/veya yaşam kalitesi arttırılabilmektedir. PSS ile 
ilişkili nörolojik hastalıklar oldukça iyi tanımlanmıştır ancak nörolojik bulgularla prezante 
olan olgularda PSS tanısı için detaylı bilgi bulunmamaktadır. 
Yön tem : Bu çalışmada nörolojik bulgular ile başvuran 11 hastada PSS tanımlanmıştır.  
Bulgular: Yedi olguda (%63,7) merkezi sinir sistemi (CNS) tutulumu belirlenirken, 4 
olguda (%36,4) periferik sinir sistemi (PNS) tutulumu saptanmıştır. 
Sonuç: Nörolojik hastalıkları nedeniyle PSS tanısı alan bu olguların değerlendirmesi 
sonucu bulgularımız şunlardır: 1) PSS’in ilk bulgusu olarak CNS tutulumu, PNS 
tutulumundan daha sık ortaya çıkmaktadır, CNS tutulumu ile giden klinik tablolardan 
en sık Multiple Skleroz (MS) benzeri hastalık ve optik nevrit görülmektedir; 2) Guillain 
Barre Sendromu (GBS) PNS tutulumu ile ilişkili en sık gözlenen klinik tablodur; 3) 
Mononöropati multipleks (MM) PSS’nin ilk işareti olabilmektedir; 4) Nörologların MS, 
optik nevrit ve GBS yanı sıra MM dâhil tüm nedeni bilinmeyen nöropati olgularının 
ayırıcı tanısında PSS düşünmesi gerekmektedir; 5) PSS ile ilişkili nörolojik tutulumu 
olan olgular için acil olarak tedavi kılavuzuna ihtiyaç bulunmaktadır.  (Nö rop si ki yat ri 
Ar fli vi 2014; 51: 148-156)
Anah tar ke li me ler: Primer Sjögren Sendromu (PSS), nörolojik bulgular, merkezi sinir 
sistemi (CNS), periferik sinir sistemi (PNS)
Çıkar çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması 
bildirmemişlerdir.
ABS TRACT
Introduction: Neurological involvements were shown in 20% of patients with Primary 
Sjogren’s Syndrome (pSS). Neurological symptoms may be the first signs of pSS in 57% 
of the cases. In addition, early diagnosis and treatment of neurological disorders may 
save or improve the quality of life of these cases. There have been reports about the 
neurologic manifestations of pSS but little is known about the details of neurologically 
presented cases. 
Met hod: In this study, we described 11 pSS patients who presented with neurological 
manifestations.  
Re sults: Central nervous system (CNS) involvement was recorded in 7 (63.7%) and 
peripheric nervous system (PNS) involvement in 4 cases (36.4%).  
Conc lu si on: Our findings regarding the cases with neurological manifestations leading 
to the diagnosis of pSS suggest that: 1) The frequency of CNS involvement was higher 
than that of PNS, and the most frequent clinical pictures of CNS involvement are Multiple 
Sclerosis (MS)-like illnesses and optic neuritis, 2) Guillain Barre Syndrome (GBS) was 
the most frequent disease of PNS involvement; 3) Mononeuropathy multiplex (MM) 
might be the first sign of pSS; 4) Neurologists should consider pSS in the differential 
diagnosis of cases with MS, optic neuritis, GBS and neuropathies of unknown causes 
including MM; 5) There is an urgent need of therapeutical guidelines for the cases with 
neurological involvement associated with pSS. (Arc hi ves of Neu ropsy chi atry 2014; 51: 
148-156) 
Key words: Primary Sjogren’s syndrome (pSS), neurological manifestations, central 
nervous system (CNS), peripheral nervous system (PNS)
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Introduction
Sjogren’s Syndrome (SS) is a chronic autoimmune disorder 
described as autoimmune epithelitis. It is characterized by 
dryness of the eyes (xerophtalmia) and mouth (xerostomia) due 
to lymphocytic infiltration of the exocrine glands (1). These two 
findings are called “sicca symptoms”. After rheumatoid arthritis, 
SS is the second most common systemic autoimmune disease 
affecting adults in the United States, with an annual incidence of 
3.9-5.3/100 000 inhabitants (2). As with other autoimmune diseases, 
SS is more common in females than in males; female to male 
ratio is 9:1 (3). SS can occur alone (primary Sjogren’s syndrome: 
PSS) or secondary in association with other connective tissue 
disorders (mainly systemic lupus erythematosus, rheumatoid 
arthritis, or scleroderma) (4,5). Approximately 50% of the patients 
have PSS (3). The exact cause of SS is not known. It is known that 
genetic, infectious, endocrine and immunological mechanisms 
contribute to the development of the disease.
The American-European Consensus Criteria for SS are now 
widely accepted (6); this set of criteria includes two subjective 
measures of ocular and oral dryness and four objective measures 
of gland involvement and elevated autoantibody titers. Having 
PSS according to this classification requires four of six criteria, of 
which at least one to be a positive minor salivary gland biopsy or 
elevated titers of SS (A) and/or SS (B) antibodies. The diagnosis 
can also be made if three of the four objective criteria are present 
(6).
However, as a systemic rheumatic disease, there can 
be various “extra-glandular” complications of SS (similar 
mononuclear infiltrates invading visceral organs or vasculitic 
lesions), at least one third of the patients present with 
neurological, rheumatologic, pulmonary, or gastrointestinal 
manifestations (7). Systemic involvement can be divided as non-
visceral (skin, arthralgia, and myalgia) and visceral involvement 
[liver, kidney, gastrointestinal, endocrine, central nervous system 
(CNS), peripheral nervous system (PNS)] (8). A wide variety 
of PNS and CNS complications are among some severe extra-
glandular complications of SS (9,10,11,12,13). 
Prevalence of PNS involvement in PSS varies widely from 10 
to 60%, with pure or predominantly sensory polyneuropathies 
as the most common neurological manifestations (sensory 
ataxic or small fiber sensory painful neuropathy) (12,14,15,16). 
Mononeuropathy multiplex (MM), polyradiculopathy, 
symptomatic dysautonomia, myopathy, cranial neuropathy and 
CNS involvement are less common. 
CNS manifestations due to PSS are still a matter of discussion 
and the reported prevalence of CNS involvement ranges from 
2% to 25% (10,11,12,13,15,17). According to Massara et al., 
CNS involvement is frequently the initial manifestation of PSS 
when mild complaints of sicca symptoms could be overlooked 
(18). CNS involvement in PSS can be seen in 4 clinical types:1) 
diffuse (encephalomyelitis, aseptic meningitis, neuropsychiatric 
dysfunctions) involvement-accounts for 40%-; 2) focal/multifocal 
(sensorial and motor deficits, brain stem, cerebellar lesions, 
seizure, migraine etc.) and spinal cord (myelopathy, transverse 
myelitis, motor neuron disease etc.) findings-about 36%-; 3) 
multiple sclerosis (MS) -like illnesses (seen in 20%-; and 4) 
isolated optic neuritis-observed in 4% of patients- (18). 
Extra-epithelial involvement (glomerulonephritis, 
polyneuropathy, vasculitis, purpura) increases morbidity and 
mortality (19). Thus, it is important to diagnose and treat these 
complications. Neurologist should be aware of neurological 
involvements of PSS which can be seen either in the course of 
the disease or as a presentation sign at onset. 
In this report, 11 cases diagnosed with PSS based on the 
neurological findings are presented. The patients’ clinical 
symptoms, neurological and laboratory findings, treatments and 
responses to the treatments are also discussed.
Methods
Eleven patients admitted to the neurology department with 
neurological findings were evaluated through detailed history 
and neurological examination. For the diagnosis, magnetic 
resonance imaging of the brain spine, electroencephalogram 
(EEG), electroneuromyography and cerebrospinal fluid (CSF) 
analyses were performed. Based on the clinical findings, further 
investigations were carried out for a definitive diagnosis. 
All patients were evaluated for the presence of a connective 
tissue disorder, symptoms of xerostomia, xerophtalmia, and ulcers 
of external genitalia and/or the oral region, and they all underwent 
routine biochemical tests and urinalysis and fibrinogen, serum 
protein electrophoresis, antinuclear antibody (ANA), anti-double 
stranded nuclear antibody (anti-dsDNA), rheumatoid factor 
(RF), anti-SS (A), and anti-SS (B) antibodies tests. Later, they 
were evaluated by an ophthalmologist, and Schirmer tests were 
conducted. Salivary gland function tests were not carried out, but 
salivary gland biopsies from 6 patients were studied. Additionally, 
CSF analysis was made in 8 patients; 3 patients refused lumbar 
puncture.
Results
1. Clinical Results
Eight of the 11 cases (72.8%) admitted to the neurology 
department were female and 3 were (27.2%) male, with a mean 
age of 41.9 years (21-67 years). Neurological manifestations had 
started with either acute or subacute patterns. All the patients 
suffered from neurological symptoms first, and later, they were 
diagnosed as having PSS. Table 1 summarizes these patients’ 
clinical, laboratory and outcome findings. Table 2 illustrates the 
diagnostic criteria of PSS for each case.
PNS manifestations were noted in 4 patients (36.4%): 3 were 
diagnosed with acute GBS due to PSS (80%), and 1 with MM. 
Seven patients (63.7%) showed signs of CNS involvement, 
2 were diagnosed with MS-like illnesses, 2 (18.2%) with cranial 
nerve involvements as isolated optic neuritis, 1 with recurrent 
form of ADEM, 1 with multiple contrast-enhanced lesions of 
the infratentorial cerebral region due to PSS, and 1 patient with 
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Table 1. Revised international classification criteria for Sjögren’s syndrome (6)
I.  Ocular symptoms: a positive response to at least one of the following questions:
1. Have you had daily, persistent, troublesome dry eyes for more than 3 months?
2. Do you have a recurrent sensation of sand or gravel in the eyes?
3. Do you use tear substitutes more than 3 times a day?
II.  Oral symptoms: a positive response to at least one of the following questions:
1. Have you had a daily feeling of dry mouth for more than 3 months?
2. Have you had recurrently or persistently swollen salivary glands as an adult?
3. Do you frequently drink liquids to aid in swallowing dry food?
III.  Ocular signs-that is, objective evidence of ocular involvement defined as a positive result for at least one of the following two tests:
1. Schirmer´s test, performed without anaesthesia (≤ 5 mm in 5 minutes).
 2. Rose-bengal score or other ocular dye score (≥4 according to van Bijsterveld´s scoring system).
IV.  Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal lymphocytic sialoadenitis, evaluated by an 
expert histopathologist, with a focus score ≥1, defined as a number of lymphocytic foci (which are adjacent to normal-appearing mucous 
acini and contain more than 50 lymphocytes) per 4 mm2 of glandular tissue.
V.  Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive result for at least one of the followinw 
diagnostic test:
1. Unstimulated whole salivary flow (≤1.5 ml in 15 minutes).
2. Parotid sialography showing the presence of diffuse sialectasiasis (punctate, caviatary or destructive pattern), without evidence of 
obstruction in the major ducts.
3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion tracer.
VI.  Autoantibodies: presence in the serum of the following autoantibodies: Antibodies to Ro (SSA) or La (SSB) antigens, or both. 
For primary SS in 7 patients without any potentially associated disease, primary SS may be defined as follows:
a) The presence of any 4 of the 6 items is indicative of primary SS, as long as either item IV Histopathology) or VI (Serology) is positive.
b) The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V, VI).
c) The classification tree procedure represents a valid alternative method for classification, although it should be more properly used in 
clinical-epidemiological survey.
Exclusion criteria
a) Past head and neck radiation treatment
b) Hepatitis C infection
c) Acquired immunodeficiency disease (AIDS)
d) Pre-existing lymphoma
e) Sarcoidois
f) Graft versus host disease
g) Use of anticholinergic drugs (since a time shorter than 4-fold the half life of the drug)
Karaca et al.
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right hemiparesia due to acute ischemic cerebral lesion in the 
posterior leg of the left internal capsule. 
2. Laboratory Results
Electrophysiological examination was performed for 7 
patients with signs and symptoms of peripheral neuropathies. 
While three of these patients showed normal results, 4 displayed 
findings compatible with peripheral neuropathy showing GBS 
in 3 cases, and MM in one patient. Of the patients with GBS, 2 
had acute demyelinating type, and 1 was with motor axonal-type 
polyradiculoneuritis. 
MRI of the brain (orbital MRI in 2 patients; spinal MRI in 6 
patients) was performed for patients with signs and symptoms of 
CNS involvements in order to assess the brain, optic nerve, spinal 
column and type of such involvements. Brain MRIs were normal 
in 3 cases; enlargements of optic nerve sheaths were observed in 
2, contrast-enhanced cerebral and/or spinal lesions in 4 patients, 
ischemic cerebral lesion was recorded in 1 patient with stroke, and 
contrast enhancements of lumbosacral radixes were established 
in 3 GBS patients. Figures 1,2,3,4 show the MRI results in PSS 
patients with CNS involvements. 
Lumbar puncture and CSF analysis were performed in eight 
patients (3 patients refused this procedure: 1 patient with cerebral 
infarction; 1 patient with optic neuritis who initially applied to the 
ophthalmology clinic and, 1 with a MS-like illness). CSF analysis 
revealed normal results in 4 patients; mild and moderate protein 
elevation and/or CSF pleocytosis were recorded in the remaining 
4 patients. Somatosensory evoked potential (SEP) recordings of 
the patients with MM, GBS and MS-like illnesses showed delayed 
responses or unresponsiveness; visual evoked potential (VEP) 
responses were also pathological in 2 cases with optic neuritis.
3. Results of the treatments
Initially, all the patients with CNS involvements were 
prescribed pulse methylprednisolone 1 gram/kg for 5-7 days. 
The 2 of GBS patients were treated with 5 cycles of therapeutic 
plasma exchange (TPE), and 1 with intravenous immunoglobulin 
(IVIg), at a dose of .4 mg/kg/day for 5 days. Following the PSS 
diagnosis, treatment was conducted by a rheumatologist and all 
the patients were treated with pulse cyclophophosphamide at a 
dose of 600 mg/m2/month for 8-19 months. Then, the treatment 
was maintained with azathioprine at a dose of 2-3 mg/kg/
day, alone or in combination with oral methylpredisolone. Oral 
methylprednisolone dosages were arranged as a dose of 1 mg/kg/
day initially, and tapered to a maintenance dose of 10-20 mg/day. 
Neurological deficits improved significantly in all patients; 
only the patient with ADEM-like picture died because of pontine 
hemorrhage during the course of treatment. 
Discussion
In our study, eleven patients were diagnosed with PSS based 
on their neurological symptoms. Of these patients, 63.7% with 
initial neurological manifestations displayed CNS manifestations, 
while 36.4% had PNS manifestations. In the report of Massara et 
al., CNS involvement was detected in 25 (5.8%) of 424 PSS patients, 
of which 13 (52%) presented with neurological manifestations and 
were later diagnosed with PSS (18). Delalande et al. retrospectively 
studied 82 patients with neurological manifestations associated 
with PSS in which neurological findings were the preceding sign 
in 47% (11). It seems obvious that in half of PSS patients, the 
disease onset is in a neurological form. However, in Delalande’s 
study, all of the neurological involvements were discussed both 
before and after the diagnosis of PSS. Nevertheless, all of the 11 
patients in our study population were diagnosed with PSS due 
to the development of neurological findings. For the previously 
diagnosed PSS cases, it was reported that neurological 
involvements had developed after a mean elapsing time of 7 (20) 
and 8.3 years (18).
Delalende and his colleagues reported similar rates of CNS 
(68%) and PNS (62%) involvements in PSS (11). As in our series, in 
their study, neurologic symptoms at the onset of PSS involved the 
CNS more frequently than PNS. Before the report of Delalende et 
al., PNS involvement was described more frequently than CNS 
involvement. They hypothesized that the highly heterogeneous 
CNS involvement in PSS in previous reports might be related 
to the different diagnostic criteria of PSS, the definition of 
neurological involvement, and the selection of patients from the 
neurology, internal medicine, or rheumatology departments. In 
our study group, all the patients were admitted to our neurology 
department, and they were later evaluated by a rheumatologist. 
It can help to reduce the potential bias in the proportion of CNS 
involvement at onset of PSS. Indeed, the high proportion of the 
CNS involvement may be related with selection of these 11 
patients from the neurology outpatient clinic.  
In our study, PNS complications were the first symptom of PSS 
in 4 patients (36.4%); 3 were diagnosed with acute GBS due to 
PSS (80%), and 1 with MM. Although there have been anecdotal 
reports about coexistence of GBS and PSS, Delalende et al. noted 
polyradiculoneuritis in only one patient with known PSS (11). MM 
is also a rare clinical entity and in the literature, to date, only 1 
patient has been reported to be diagnosed with PSS after the 
Figure 1. Contrast enhanced T1 weighted image revealed multiple, 
expansive hypointense lesions with contrast enhancements (Patient 1; 
Acute demyelinating encephalomyelitis (ADEM)-like picture due to primary 
Sjogren’s Syndrome)
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diagnosis of MM (21). We suggest that the systematic screening 
for PSS is needed in cases of MM and polyradiculoneuritis as 
well as in cases of sensory, autonomic or trigeminal neuropathies 
of unknown causes.
Recent data concerning CNS involvement in PSS confirms 
the heterogeneity of clinical presentations that may mimic stroke 
or MS. In a report by Govoni et al., over a period of 5 years, 
CNS involvement was detected in 7 of 87 (8%) of unselected 
consecutive patients whose previous diagnosis was PSS (22). In 
our study, we identified 63.7% of patients (7/11) with CNS findings 
as initial clinical presentations of PSS; 5 of our patients had focal 
brain involvements yielding MS-like illnesses in 2 cases; one 
patient had recurrent ADEM-like disease, infratentorial cerebral 
involvement, and acute ischemic stroke. Optic neuritis was 
observed in 2 patients. 
MS-like syndromes could represent a particular subset of 
neuro-Sjögren, and may thus affect the outcome. One tenth to 
one third of the neurological forms of PSS cases presents with 
pictures like MS (9,11). Some researchers have also reported 
an increased frequency of PSS in patients with MS (20). In our 
study, 18.2% of the cases were diagnosed with MS-like illnesses. 
Although the rate is fairly high, when the patient showing ADEM-
like picture is included, the rate would be much higher (27.3%). 
Therefore, a screening test for PSS should be considered in 
suspected MS cases. Delalende and coworkers described 23 
of 82 patients (28%) with a clinical feature suggesting MS; they 
also observed that the delay between onset and the diagnosis of 
PSS was significantly longer (9.8 years) for their 10 patients with 
recurrent deficits mimicking relapsing-remitting MS (11). Thus, 
this finding underlines the need for screening test in PSS for the 
exact diagnosis in such MS-like cases. The neuroradiological 
features with serologic and CSF analysis could help to distinguish 
between these two inflammatory CNS diseases. MRI lesions are 
generally smaller and less pronounced in PSS than in MS (23). 
There are some characteristic features of MS-like illnesses of 
PSS, however, affecting patients of older age, involvement of PNS 
and/or cranial nerve, spinal cord MRI lesions spanning multiple 
spinal segments, MRI lesions of cerebral cortex, and absence of 
lesions in the corpus callosum are all atypical in MS (20,23,24). As 
it was also observed in our patients, the CSF profile of PSS strongly 
resembles the profile described in MS patients, yet in MS, there 
are multiple bands, often more than 3, whereas 1 or 2 bands can 
mostly be detected in PSS patients (9). Oligoclonal band studies 
Figure 2. Axial fluid-attenuated inversion recovery (FLAIR) image 
demonstrates hyperintense lesions in pons (Patient 5; infratentorial 
cerebral lesions due to primary Sjogren’s Syndrome)
Figure 3. T2 weighted MRI images showed hyperintense lesion from 
medullar to C1 region (Patient 8; Multiple Sclerosis-like illness due to 
primary Sjogren’s Syndrome)
Figure 4. T1 weighted post-contrast image of the cervical spine revealed 
contrast enhancement at the C1 and C3-4 region (Patient 11; Multiple 
Sclerosis-like illness due to primary Sjogren’s Syndrome)
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in our patients yielded negative results. Furthermore, Alexander 
et al. reported that the bands disappeared as a response to 
corticosteroid therapy in most neuro-Sjögren patients, contrary 
to that in those with MS (9).
Most of the cases with CNS manifestations associated 
with PSS had an acute, often recurrent course (11,18). It was 
concluded that severe disability was more frequent in cases of 
CNS involvement than in cases of PNS involvement, suggesting 
the need for intensive and early treatment in cases of CNS 
involvement (11). Contrary to this conclusion, spontaneous 
remission or only mild neurological impairment was deduced in 
patients with CNS involvement of PSS in another study (18). In 
line with the findings in the literature, the disease course of our 
patients with CNS involvements was in either acute or subacute 
fashion, and most of the patients recovered markedly (particular 
improvements were recorded in 4 patients) in spite of their serious 
clinical presentations. Only one patient with recurrent ADEM-like 
illness died due to a large pontine hemorrhage. 
Bragoni reported a young woman with ischemic stroke as 
initial manifestations of SS (25). In our study, we defined PSS in a 
young man with right hemiparesia due to acute ischemic cerebral 
lesion in the posterior limb of the left internal capsule. Therefore, 
PSS should be considered among the causes of stroke, especially 
in young patients. 
Although, optic neuritis was reported in 13 (15.9%) patients in 
Delalende’s series of 82 patients with PSS, abnormal VEPs were 
obtained in 61% of tested patients (11). They did not provide any 
information on whether these optic involvements were seen at 
the onset or during the course of the disease. We defined isolated 
either unilateral or bilateral optic neuritis in two cases (18.2%) 
as initial manifestations of PSS, and, we also recommend the 
systematic screening for PSS in cases with optic neuropathy. 
Treatments usually comprise symptomatic approach in milder 
cases, nevertheless, pulse cyclophosphamide and steroids 
or other immunosuppressants (chlorambucil or azathioprine) 
are required in cases with progressive symptoms leading to 
neurological impairment. We achieved fairly reliable results with 
TPE and IVIg in cases with GBS and, we used corticosteroids 
in a certain number of our patients. The need for therapeutic 
guidelines is obvious, and further research should be conducted 
to gain deeper insight into this area. It was demonstrated that 
corticosteroid therapy is a likely candidate for MM and multiple 
cranial neuropathies (26,27), and favorable improvement may 
be seen in painful dysaesthesia of painful sensory neuropathy 
and radiculoneuropathy forms with IVIg therapy (27,28,29,30). 
In addition to corticosteroids and IVIg, plasmapheresis (31), 
D-penicillamine (32), anti-TNF agent, and infliximab (33) have been 
used with variable responses. Patients with myelopathy or MM 
have responded well to cyclic application of cyclophosphamide 
(11). Alexander recommends cyclophosphamide pulse therapy 
combined with a corticosteroid therapy for at least one year in 
the beginning (34). We applied 8-19 cycles of cyclophosphamide 
in our patients, and significant improvements were achieved. 
Randomized controlled studies are needed to assess the actual 
efficacy of these treatments for neuro-Sjögren syndrome. 
Conclusions 
In this study, we reported 11 patients with PSS, whose initial 
manifestations were neurological, and our conclusions from this 
series of patients are listed below;
1. CNS involvement was the major presenting form at a rate of 
63.7% in this group of patients; PNS involvement was established 
in 36.4%. MS-like illnesses and optic neuritis were the most 
frequent forms of CNS involvements.
2. GBS was the top initial clinical diagnosis in patients with 
PNS involvements, unlike what is suggested by previous studies 
illustrating sensory ataxic neuropathy in cases with PSS. We can, 
thus, state that sensory ataxic neuropathy occurs in advanced 
PSS cases.
3. Differential diagnosis for PSS could be performed in cases 
with optic neuritis, MS, GBS and ischemic stroke. Complete 
laboratory testing, including SS (A&B) antibody studies, and 
ophthalmological and salivary gland evaluation may lead to more 
reliable diagnosis.
4. Suspicion of PSS should be accounted for when evaluating 
patients (particularly females) with unknown causes of 
neuropathy including MM. Additionally, patients with atypical 
neurological findings (either clinical or radiological) deserve 
this evaluation, and rheumatological consultation should be 
requested for such cases. 
5. Multi-centered, randomized, prospective, carefully 
controlled trials with quantitative neurological and patient-
centered outcome measures should be conducted in order to 
obtain therapeutic guidelines. 
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